+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Status Unknown

Phase 2
Age: 18Years +
All Genders
ID00002414

Randomized, Double-Blind, Parallel Group, Placebo Controlled, Tolerability, Safety and Pilot Efficacy Study of CPI-1189 in HIV Infected Individuals With Cognitive and Motor Impairment

Led by Centaur Pharmaceuticals · Updated on 2005-06-24

60

Participants Needed

6

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

The purpose of this study is to see if it is safe and effective to give CPI-1189 to patients with AIDS dementia. Advanced HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down.

CONDITIONS

Brief Title

Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here